NLRP3 and dermatomyositis: Our observations further align with previous clinical and preclinical studies which showed that STS exhibits a strong anti-inflammatory action in dermatomyositis and atopic dermatitis by reducing the levels of pro-inflammatory cytokines in the serum of patients as well as immune cell infiltration and inhibition of NLRP3 inflammasome in the skin of mice with atopic dermatitis, which contributed to improved skin condition [33,34,35].